Tamoxifen-related porphyria cutanea tarda
Abstract
Tamoxifen-related porphyria cutanea tarda. We report a case of porphyria cutanea tarda (PCT) in a patient with breast cancer following adjuvant tamoxifen. Cessation of tamoxifen resulted in a prompt decline in urinary porphyrins suggestive of a causative role. Tamoxifen is known to be hepatotoxic however, its association with PCT is unclear. In this report, we discuss the porphyrinogenicity of tamoxifen and potential mechanisms.
Collections
Subject
tamoxifen porphyria cutanea tarda breast cancer nonalcoholic steatohepatitis estrogen
License start date
2002
Citation
MEDICAL ONCOLOGY, 2002, 19 (2), pp. 121 - 123